New primary cancers can occur in patients with a previous cancer. Among the risk factors, therapies such as chemotherapy, radiotherapy, and hormonal therapy have been associated with the development of neoplasms. Second cancers most commonly develop 5–10 years after the initial tumor. We observe the implications of cancer-related therapy in the development of a new tumor. We looked at 602 patients who had their first cancer diagnosed in 2011 and calculated the number of different primary cancers between 2011 and 2016 for each patient. Twenty-four patients had a second cancer within 5 years from the first diagnosis and there were no patients with a third cancer. There was no statically significant difference in the rates of second cancers after exposure to chemotherapy, radiotherapy, hormonal therapy, or any combination of these (p=0.738). Of the second cancers reported after 2011, renal, uterine, cervical, and lung cancers were the most frequently reported. Additionally, there was no statically significant difference among the rates of second cancers in men versus women (p=0.467), as well as among whites versus blacks (p=0.318). We conclude that while new primaries can occur after one cancer, there was no increased risk after exposure to different cancer-related therapies. With increased focus on the primary disease, there is a higher likelihood of missing another primary lesion. This is important as the practical implications of managing multiple primaries are rarely discussed.
- drug-related side effects and adverse reactions
Statistics from Altmetric.com
Contributors KS, ES, RK, SM, SG, CS, and FR all equally participated in the drafting of the protocol, collection of data, literature search and writing of the manuscript. KS and FR both revised the final written manuscript.
Funding This study was awarded the Resident’s Dean’s Grant from the University of Florida College of Medicine, Jacksonville. Funds from this grant was used only for attending conferences and covering the publication fee of the study.
Competing interests None declared.
Patient consent Not required.
Ethics approval University of Florida College of Medicine, Jacksonville, IRB committee.
Provenance and peer review Not commissioned; externally peer reviewed.
Presented at The abstract was submitted to the ASCO Annual Meeting of 2018 for poster presentation, and presented as a poster presentation at the Florida ACP Internal Medicine Chapter in Florida 2018 and the 2018 AFMR Midwestern Regional Meeting.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.